Evidence map›Paper›PMID 34389725›Full record

ArticleNature communications2021

A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells.

Rebecca A Dagg, Gijs Zonderland, Emilia Puig Lombardi, Giacomo G Rossetti, Florian J Groelly, Sonia Barroso, Eliana M C Tacconi, Benjamin Wright, Helen Lockstone, Andrés Aguilera and 2 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Rebecca A DaggGenome Stability and Tumourigenesis Group, MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0002-3023-9616
Gijs ZonderlandGenome Stability and Tumourigenesis Group, MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0002-4820-6273
Emilia Puig LombardiGenome Stability and Tumourigenesis Group, MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.
Giacomo G RossettiDepartment of Molecular Biology, University of Geneva, Geneva, Switzerland.ORCID 0000-0002-8272-2925
Florian J GroellyGenome Stability and Tumourigenesis Group, MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0001-7699-7108
Sonia BarrosoCentro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER), Universidad de Sevilla-Consejo Superior de Investigaciones Científicas-Universidad Pablo de Olavide, Seville, Spain.ORCID 0000-0002-0062-2016
Eliana M C TacconiGenome Stability and Tumourigenesis Group, MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0002-4118-4286
Benjamin WrightBioinformatics and Statistical Genetics Core, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
Helen LockstoneBioinformatics and Statistical Genetics Core, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
Andrés AguileraCentro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER), Universidad de Sevilla-Consejo Superior de Investigaciones Científicas-Universidad Pablo de Olavide, Seville, Spain.ORCID 0000-0003-4782-1714
Thanos D HalazonetisDepartment of Molecular Biology, University of Geneva, Geneva, Switzerland.
Madalena TarsounasGenome Stability and Tumourigenesis Group, MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK. madalena.tarsounas@oncology.ox.ac.uk.ORCID 0000-0002-4273-2870
University of Oxford · GBCentre for Human Genetics · GBConsejo Superior de Investigaciones Científicas · ESUniversity of Geneva · CHUniversity of Copenhagen · DK

Funding

Cancer Research UK
6 · The paper itself

Abstract

BRCA1 or BRCA2 germline mutations predispose to breast, ovarian and other cancers. High-throughput sequencing of tumour genomes revealed that oncogene amplification and BRCA1/2 mutations are mutually exclusive in cancer, however the molecular mechanism underlying this incompatibility remains unknown. Here, we report that activation of β-catenin, an oncogene of the WNT signalling pathway, inhibits proliferation of BRCA1/2-deficient cells. RNA-seq analyses revealed β-catenin-induced discrete transcriptome alterations in BRCA2-deficient cells, including suppression of CDKN1A gene encoding the CDK inhibitor p21. This accelerates G1/S transition, triggering illegitimate origin firing and DNA damage. In addition, β-catenin activation accelerates replication fork progression in BRCA2-deficient cells, which is critically dependent on p21 downregulation. Importantly, we find that upregulated p21 expression is essential for the survival of BRCA2-deficient cells and tumours. Thus, our work demonstrates that β-catenin toxicity in cancer cells with compromised BRCA1/2 function is driven by transcriptional alterations that cause aberrant replication and inflict DNA damage.

Indexed as

beta CateninBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsCell Line, TumorCell ProliferationCells, CulturedCell SurvivalCyclin-Dependent Kinase Inhibitor p21DNA DamageFemaleGene Expression ProfilingHeLa CellsHumansOncogenesOvarian Neoplasmsbeta CateninBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanCyclin-Dependent Kinase Inhibitor p21

Identifiers

PMID34389725
PMCPMC8363664
OpenAlexW3191787531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.